Valuation
- Market cap
- 2,248,709,000
- Revenue TTM
- $255,870,000
- Net income TTM
- $-103,270,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -40.36%
- Debt to equity
- 0.00
Trading
- Volume
- 3,052,700
- Avg volume
- 1,745,644
- Day's range
- $29.28 – $31.14
- Shares out
- 73,825,000
- Stochastic %K
- 55%
- Beta
- 1.61
- Analysts
- Strong Sell
- Price target
- $21.43
Company profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for...
Show more
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- Industry
- Health Information Services
- Sector
- Healthcare
- Phone
- 212 295 5800
- Website
- https://www.schrodinger.com
- Address
- 1540 Broadway, 24th Floor, New York, United States
Latest news
No headlines yet.
